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eta-Blocker–Induced Heart Rate
owering and Cardiovascular
utcomes the Result of
onfounding by Indication?
n a meta-analysis of beta-blocker trials for the treatment of
ypertension, Bangalore et al. (1) report that there is an inverse
elationship between achieved heart rate at the end of the trials and
isk of myocardial infarction and cardiovascular death. The authors
uggest that the heart rate decrease associated with beta-blockers
eads to increased central aortic pressure, and that this phenome-
on is the cause of increased adverse events associated with lower
eart rate. However, this study and conclusion are subject to
everal sources of residual confounding, including indication bias.
t is well known in cardiovascular trials that patients who require
igher doses of medication are almost always those with the worst
ardiovascular disease; the converse is also true. In their limitation
ection, the authors note that they were unable to determine the
ose of beta-blocker used. However, based on the pharmacology of
eta-blockers, it is highly likely that the achieved heart rate is
losely correlated with the dose of beta-blocker that was required
o achieve blood pressure control. In addition, many of the trials
hat the authors included in their meta-analysis were conducted
efore the era of ambulatory blood pressure monitoring, and
herefore included patients with white coat hypertension, who are
t low risk for cardiovascular events. In these low-risk patients,
lood pressure would most likely have been controlled with a low
ose of beta-blockers, and therefore they would have had higher
eart rates and few cardiovascular events.
Although these potential confounding factors are difficult to test
n a post-hoc fashion, the authors should have the data to answer
he question of the relationship between achieved heart rate and
chieved blood pressure, as well as the relationship between
chieved heart rate and percentage of patients achieving goal blood
ressure. If these analyses demonstrate an inverse relationship
etween heart rate and measures of blood pressure control, then it
ould suggest that the authors’ findings simply reflect the fact that
ore difficult to control patients require higher doses of antihy-
ertensive medication—in this case, a beta-blocker.
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tenolol Versus Other
eta-Adrenergic Blockers
he question is: Does atenolol differ from other beta-adrenergic
lockers in clinical outcome? Bangalore et al. (1) nicely related
nfavorable trial outcomes to the degree of pulse rate reduction
nduced by beta-adrenergic blockers. But is it not a mistake to
nclude the HAPPHY (Heart Attack Primary Prevention in
ypertension) trial without considering that the 2 beta-adrenergic
lockers arms differed as to outcome (2)? Patients on atenolol
howed higher death rates and patients on metoprolol showed
ower death rates than did patients taking diuretics. The difference
etween the 2 outcomes was not by itself statistically significant
results with other end points were neither reported nor provided
n request). But together with a borderline significant difference
etween atenolol and other beta-adrenergic blockers in a meta-
nalysis of beta-adrenergic blockers in hypertension using a Bayes-
an approach (3) without including the HAPPHY trial, we do
hink that atenolol is inferior to other beta-adrenergic blockers. It
hould be underscored that atenolol differs markedly from most
ther beta-adrenergic blockers by being water soluble and thus
lmost unable to enter the central nervous system. This seems to
xplain why atenolol did not stimulate the vagal nerves by an action
n the central nervous system, as metoprolol did (4).
We therefore suggest that the conclusion drawn by Bangalore
t al. (1) should be restricted to atenolol only. Atenolol does not
eem to be an appropriate representative for the whole class of
eta-adrenergic blockers, although unfortunately it is widely used.
his should be considered when interpreting results from clinical
rials on beta-adrenergic blockers and when designing new trials.
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